Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry
Language English Country Great Britain, England Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
21536664
DOI
10.1093/annonc/mdr065
PII: S0923-7534(19)34378-9
Knihovny.cz E-resources
- MeSH
- Benzenesulfonates administration & dosage MeSH
- Adult MeSH
- Phenylurea Compounds MeSH
- Indoles administration & dosage MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy secondary MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy secondary MeSH
- Niacinamide analogs & derivatives MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyridines administration & dosage MeSH
- Pyrroles administration & dosage MeSH
- Registries * MeSH
- Retrospective Studies MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Sorafenib MeSH
- Sunitinib MeSH
- Protein-Tyrosine Kinases antagonists & inhibitors MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Benzenesulfonates MeSH
- Phenylurea Compounds MeSH
- Indoles MeSH
- Protein Kinase Inhibitors MeSH
- Niacinamide MeSH
- Pyridines MeSH
- Pyrroles MeSH
- Sorafenib MeSH
- Sunitinib MeSH
- Protein-Tyrosine Kinases MeSH
BACKGROUND: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib-sorafenib or sorafenib-sunitinib sequence. PATIENTS AND METHODS: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib-sorafenib sequence and 122 patients treated with sorafenib-sunitinib sequence. RESULTS: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib-sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib-sorafenib and 84% (95% CI 77% to 91%) for sorafenib-sunitinib patients (P = 0.99). Treatment toxic effects were predictable but a significant proportion of patients (up to 14%-25% for different lines of therapy and used TKI) switched between TKIs or discontinued TKI therapy because of toxicity. CONCLUSIONS: In contrast to most of the previously published reports, we have not observed improved PFS or OS for mRCC patients treated with the sorafenib-sunitinib sequence as compared to the sunitinib-sorafenib sequence.
References provided by Crossref.org
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
Neopterin as a biomarker of immune response in cancer patients
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
